We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Cellectar

News List

Cellectar Receives FTD for Diffuse Large B-Cell Lymphoma Treatment contractpharma
July 10, 2019
Drug conjugate, CL131, delivers cytotoxic radiation directly and selectively to cancer cells.
Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma drugs
May 20, 2019
Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma.
Cellectar Gains FDA Fast Track for CLR 131 in MM contractpharma
May 16, 2019
CLR 131 is being evaluated in a Phase II study in patients with relapsed or refractory multiple myeloma and other select B-Cell lymphomas.
Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s Sarcoma firstwordpharma
July 10, 2018
Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces that the U.S.
Jobs Lost as Cellectar Biosciences Shutters Manufacturing Operations biospace
January 10, 2018
Cellectar Biosciences is closing its manufacturing operations and contracting them out. As a result, it expects to lay off six of its 16 employees.